GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025
GSK plc (GSK) announced today that the FDA approved Exdensur (depemokimab‑ulaa) for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc (LSE/NYSE: GSK) is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur (depemokimab‑ulaa)—a new twice‑yearly biologic for severe asthma—while also releasing its latest share buyback update through a regulatory filing. Investegate+1 Below is a full, reader-friendly rundown of all current GSK news items dated 17.12.2025, plus what they signal for patients, clinicians, and investors. Today’s GSK headlines (17.12.2025) 1)